Compare Moderna, Inc. (MRNA) vs Boston Beer Company Inc (SAM) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Moderna, Inc. vs Boston Beer Company Inc — how do they compare? Moderna, Inc. trades at $60.51 (market cap $23.88B), while Boston Beer Company Inc trades at $179.73 (market cap $1.86B). The key difference: Moderna, Inc. is far larger — about 12.8× Boston Beer Company Inc's market cap, and Moderna, Inc. is trading nearer its 52-week high, Boston Beer Company Inc nearer its low. Which is the better fit depends on your goals.
| MRNA | SAM | |
|---|---|---|
Market Cap | $23.88B | $1.86B |
Sector | Health | Consumer Staples |
52-Week High | $81.80 | $260.05 |
52-Week Low | $22.36 | $161.08 |
Enterprise Value | $20.03B | $1.63B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Moderna (MRNA) stock trades at $59.17, up 9.86% recently, with a bullish technical signal and strong institutional buying interest. The company's Q2 2026 earnings beat expectations, and the FDA approval of its mRNA flu vaccine, mFLUSIVA, for adults 50+ marks a key post-pandemic milestone. However, fundamentals show declining revenue from $18.9B in 2022 to $1.9B in 2025 and persistent net losses, with a negative net income margin of -142.58% in 2025.
The outlook hinges on pipeline execution; while new vaccine approvals and cost-cutting efforts offer growth potential, the stock faces risks from high valuation multiples and ongoing profitability challenges. Analyst consensus is cautious with a $54.33 price target below the current price, reflecting mixed sentiment amid transitional phase uncertainties.
The Boston Beer Company (SAM) trades at $186.61, up 1.94% on the day, with a bullish technical signal driven by moving averages. The stock shows mixed fundamentals; while the P/E ratio of 22.66 and P/S of 0.99 suggest reasonable valuation, recent quarterly earnings have missed expectations, and the company faces volume declines in core brands. Positive cash flow and innovation in ready-to-drink products provide some offset. Analyst sentiment is cautious, with a consensus price target of $207.33 but a majority hold rating.
Outlook: Upside exists if new product growth accelerates and margins improve, but risks from weak demand and competitive pressure persist. The stock's trajectory hinges on reversing volume trends and achieving future earnings targets, making it a hold for now with watchful optimism.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Moderna, Inc.
Moderna, Inc. operates as a clinical stage biotechnology company. The Company focuses on the discovery and development of messenger RNA (mRNA) therapeutics and vaccines. Moderna develops mRNA medicines for infectious, immuno-oncology, and cardiovascular diseases.
Read more on MRNA →About Boston Beer Company Inc
Boston Beer is a leader in U.S. high-end malt beverages and adjacent categories, with strong positions in craft beer, hard cider, and hard seltzer. The firm sells an array of flavor variants and package sizes, predominantly centered around four priority brands: Samuel Adams, Angry Orchard, Twisted Tea, and Truly Hard Seltzer. Its drinks are produced in both company-owned breweries as well as through third-party contract arrangements, and while the company primarily goes to market through independent wholesalers (as mandated by law), it operates a fairly large salesforce to induce demand across the value chain (distributors, retailers, and drinkers). The preponderance of revenue is generated domestically.
Read more on SAM →
